NDAINTRAVENOUSSOLUTION
Approved
Aug 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
FOCINVEZ (fosaprepitant dimeglumine) by Aspiro Therapeutics is accordingly, its antiemetic effects are attributable to aprepitant. First approved in 2023.
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOCINVEZ is an intravenous fosaprepitant dimeglumine solution approved in August 2023 for chemotherapy-induced nausea and vomiting (CINV) prevention. It is a selective NK1 receptor antagonist that crosses the blood-brain barrier to block substance P signaling, complementing 5-HT3 antagonists and corticosteroids in managing acute and delayed emesis. The IV formulation provides an alternative to oral aprepitant for patients requiring parenteral administration.
Peak12.2 years to LOE
Recently approved asset in peak commercialization phase with nascent market adoption; team building and market penetration represent near-term growth opportunities.
Mechanism of Action
accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Started Sep 2012
1,015 enrolled
Chemotherapy-Induced Nausea and Vomiting (CINV)
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
Started Aug 2008
34 enrolled
Breakthrough Nausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific
Worked on FOCINVEZ at Aspiro Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.